系统性红斑狼疮成人多重用药的横断面研究
该横断面研究基于美国亚特兰大基于人群的经确认SLE成人队列(n=451),通过自我报告的药物评估多重用药(≥5种处方或非处方药)的患病率。56.3%的参与者报告多重用药,年龄≥60岁、较高疾病活动度、累积损伤、较长病程及使用3-5种免疫调节药物与较高的年龄调整患病率相关。羟氯喹(71.4%)、糖皮质激素(44.3%)常见,但多重用药最常由降压药(61.9%)、非阿片类止痛药(51.7%)等其他药物驱动。
要点
- 56.3%的SLE成人报告多重用药(≥5种处方或非处方药)。
- 年龄≥60岁、较高疾病活动度、累积损伤、较长病程及使用3-5种免疫调节药物与较高的年龄调整多重用药患病率相关。
- 多重用药最常由降压药(61.9%)、非阿片类止痛药(51.7%)等其他药物驱动。
核心结论
- SLE成人中多重用药常见,需通过个体化药物优化策略处理处方和非处方药负担。
研究设计与样本
- 横断面研究,参与者来自美国佐治亚州亚特兰大基于人群的经确认SLE成人队列,共451人。
- 处方和非处方药在访视时自我报告,多重用药定义为≥5种处方或非处方药。
主要发现
- 56.3%的参与者报告多重用药。
- 年龄≥60岁、40-59岁、18-39岁的多重用药年龄调整患病率分别为68.1%、59.8%、43.0%。
- 较高疾病活动度vs较低者年龄调整患病率为65.8% vs 46.2%,累积SLE相关损伤有vs无者为68.5% vs 42.4%。
- 较长病程vs较短者年龄调整患病率为62.4% vs 50.0%,使用3-5种vs 0-1种免疫调节药物者为79.6% vs 38.0%。
- 性别、种族或教育程度间的多重用药患病率无统计学显著差异。
关键数值与推荐
- 多重用药定义为≥5种处方或非处方药。
- 羟氯喹使用率71.4%,糖皮质激素44.3%,其他免疫调节药物50.3%。
- 多重用药最常由其他药物驱动:降压药61.9%、非阿片类止痛药51.7%、过敏治疗22.4%、抗抑郁药22.2%、胃反流药物21.7%。
临床怎么用
- 原文建议通过个体化药物优化策略处理SLE患者使用的处方和非处方药负担。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Estimates of polypharmacy among US adults with systemic lupus erythematosus (SLE)-a relatively young and disproportionately minoritized population-remain sparse. We sought to estimate the prevalence of polypharmacy in SLE and identify the most common medications used. METHODS: For this cross-sectional study, participants were recruited from a population-based cohort of adults with validated SLE in Atlanta, Georgia. Prescription and over-the-counter (OTC) medications were self-reported at the study visit. Polypharmacy was defined as five or more prescription or OTC medications. Estimates of polypharmacy prevalence by key sociodemographic and SLE-related participant characteristics were obtained using crude logistic regression and postestimation marginals. RESULTS: More than half (56.3%) of participants (n = 451; 15.3% ≥60 years old, 91.8% women, and 81.8% Black) reported polypharmacy. Older age (68.1%, 59.8%, and 43.0% for ages ≥60 years, 40-59 years, and 18-39 years), higher vs lower disease activity (65.8% vs 46.2%) and cumulative SLE-related damage (68.5% vs 42.4%), longer disease duration (62.4% vs 50.0%), and taking three to five vs zero to one immunomodulating medications (79.6% vs 38.0%) were associated with higher age-adjusted prevalence of polypharmacy; prevalence was not statistically significantly different by sex, race, or education. Although hydroxychloroquine (71.4%), glucocorticoids (44.3%), and other immunomodulating drugs (50.3%) were common, polypharmacy was most often driven by other medications, such as antihypertensives (61.9%), nonopioid pain relievers (51.7%), allergy treatments (22.4%), antidepressants (22.2%), and gastric reflux medications (21.7%). CONCLUSION: Our results underscore the need to address the burden of medication regimens in this population through individualized medication optimization strategies that account for prescription and OTC medications used by those with SLE.
引用
- Yang J, Growdon ME, Fitzpatrick J, et al. Polypharmacy in Adults With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2026. PMID: 41132137. doi:10.1002/acr.25686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。